Avalon GloboCare (NASDAQ:ALBT) Stock Price Down 0.7% – Here’s What Happened

Avalon GloboCare Corp. (NASDAQ:ALBT) shares dropped 0.7% on Monday . The company traded as low as $0.2779 and last traded at $0.28. Approximately 177,393 shares were traded during trading, a decline of 84% from the average daily volume of 1,121,802 shares. The stock had previously closed at $0.2820.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Avalon GloboCare Price Performance

The company has a market capitalization of $3.37 million, a price-to-earnings ratio of -0.08 and a beta of -0.06. The stock has a fifty day simple moving average of $0.36 and a 200-day simple moving average of $0.69.

Avalon GloboCare (NASDAQ:ALBT) last released its quarterly earnings data on Monday, March 30th. The company reported $0.46 EPS for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.